A role for transient receptor potential vanilloid 4 in tonicity-induced neurogenic inflammation.
OBJECTIVE
Changes in extracellular fluid osmolarity, which occur after tissue damage and disease, cause inflammation and maintain chronic inflammatory states by unknown mechanisms. Here, we investigated whether the osmosensitive channel, transient receptor potential vanilloid 4 (TRPV4), mediates inflammation to hypotonic stimuli by a neurogenic mechanism.


METHODS
TRPV4 was localized in dorsal root ganglia (DRG) by immunofluorescence. The effects of TRPV4 agonists on release of pro-inflammatory neuropeptides from peripheral tissues and on inflammation were examined.


RESULTS
Immunoreactive TRPV4 was detected in DRG neurones innervating the mouse hindpaw, where it was co-expressed in some neurones with CGRP and substance P, mediators of neurogenic inflammation. Hypotonic solutions and 4alpha-phorbol 12,13-didecanoate, which activate TRPV4, stimulated neuropeptide release in urinary bladder and airways, sites of neurogenic inflammation. Intraplantar injection of hypotonic solutions and 4alpha-phorbol 12,13-didecanoate caused oedema and granulocyte recruitment. These effects were inhibited by a desensitizing dose of the neurotoxin capsaicin, antagonists of CGRP and substance P receptors, and TRPV4 gene knockdown or deletion. In contrast, antagonism of neuropeptide receptors and disruption of TRPV4 did not prevent this oedema. TRPV4 gene knockdown or deletion also markedly reduced oedema and granulocyte infiltration induced by intraplantar injection of formalin.


CONCLUSIONS
Activation of TRPV4 stimulates neuropeptide release from afferent nerves and induces neurogenic inflammation. This mechanism may mediate the generation and maintenance of inflammation after injury and during diseases, in which there are changes in extracellular osmolarity. Antagonism of TRPV4 may offer a therapeutic approach for inflammatory hyperalgesia and chronic inflammation.
INSERM, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France. nathalie.vergnolle@inserm.fr
N
N
Vergnolle
N
N
Cenac
C
C
Altier
L
L
Cellars
K
K
Chapman
G W
GW
Zamponi
S
S
Materazzi
R
R
Nassini
W
W
Liedtke
F
F
Cattaruzza
E F
EF
Grady
P
P
Geppetti
N W
NW
Bunnett
D000818:Animals; D004195:Disease Models, Animal; D004487:Edema / Q000503:physiopathology; D045604:Extracellular Fluid / Q000378:metabolism; D005260:Female; D005455:Fluorescent Antibody Technique; D005727:Ganglia, Spinal / Q000378:metabolism; D006098:Granulocytes / Q000378:metabolism; D007038:Hypotonic Solutions; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020078:Neurogenic Inflammation / Q000503:physiopathology*; D009475:Neurons, Afferent / Q000378:metabolism; D009479:Neuropeptides / Q000378:metabolism*; D009994:Osmolar Concentration; D050916:TRPV Cation Channels / Q000819:agonists / Q000235:genetics / Q000378:metabolism*
D007038:Hypotonic Solutions; D009479:Neuropeptides; D050916:TRPV Cation Channels; C486576:Trpv4 protein, mouse